Literature DB >> 21487835

Natalizumab and HSV meningitis.

Erica Seiguer Shenoy1, Eleftherios Mylonakis, Rocio M Hurtado, Nagagopal Venna.   

Abstract

Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn's disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21487835      PMCID： PMC3105891          DOI： 10.1007/s13365-011-0027-4

Source DB:  PubMed          Journal:  J Neurovirol        ISSN： 1355-0284            Impact factor:   2.643


  8 in total

1.  Alpha4 integrins as therapeutic targets in autoimmune disease.

Authors:  Ulrich H von Andrian; Britta Engelhardt
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

2.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

Authors:  Annette Langer-Gould; Scott W Atlas; Ari J Green; Andrew W Bollen; Daniel Pelletier
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

3.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

Review 4.  Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.

Authors:  Karin A Thursky; Leon J Worth; John F Seymour; H Miles Prince; Monica A Slavin
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

Review 5.  Neurological complications of herpes simplex virus type 2 infection.

Authors:  Joseph R Berger; Sidney Houff
Journal:  Arch Neurol       Date:  2008-05

6.  Natalizumab for active Crohn's disease.

Authors:  Subrata Ghosh; Eran Goldin; Fiona H Gordon; Helmut A Malchow; Jørgen Rask-Madsen; Paul Rutgeerts; Petr Vyhnálek; Zdena Zádorová; Tanya Palmer; Stephen Donoghue
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

7.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

8.  A controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245
  8 in total
  13 in total

Review 1.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 2.  Infectious Complications of Novel Multiple Sclerosis Therapies.

Authors:  S N Levin; T B Kaplan
Journal:  Curr Infect Dis Rep       Date:  2017-02       Impact factor: 3.725

Review 3.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

4.  Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.

Authors:  Jennifer Yeung; Cécile Cauquil; Guillaume Saliou; Ghaida Nasser; Sophio Rostomashvili; David Adams; Marie Théaudin
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

Review 5.  Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes.

Authors:  Jan Lycke
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

Review 6.  Natalizumab therapy for multiple sclerosis.

Authors:  Jeremy Chataway; David H Miller
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

7.  Bacterial meningitis in a patient with multiple sclerosis receiving Tysabri.

Authors:  Abdorreza Naser Moghadasi; Soroor Advani; Shiva Rahimi
Journal:  Iran J Neurol       Date:  2016-07-06

Review 8.  The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.

Authors:  Gabriel Pardo; David E Jones
Journal:  J Neurol       Date:  2017-09-06       Impact factor: 4.849

9.  Clinical use of anti-TNF therapy and increased risk of infections.

Authors:  Tauseef Ali; Sindhu Kaitha; Sultan Mahmood; Abdul Ftesi; Jordan Stone; Michael S Bronze
Journal:  Drug Healthc Patient Saf       Date:  2013-03-28

10.  Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.

Authors:  Xenia Kobeleva; Florian Wegner; Inez Brunotte; Mete Dadak; Reinhard Dengler; Martin Stangel
Journal:  J Neuroinflammation       Date:  2014-01-30       Impact factor: 8.322
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.